Persistence and adherence to second-generation antipsychotic long-acting injectable medications for schizophrenia: A comparative study in the Australian context.
Australas Psychiatry
; 31(1): 76-81, 2023 02.
Article
em En
| MEDLINE
| ID: mdl-36475909
ABSTRACT
OBJECTIVE:
To examine patient characteristics, persistence and adherence to treatment associated with use of second-generation antipsychotic long-acting injectable (SGA LAI) medications in the Australian real-world setting.METHOD:
Five SGA LAIs were compared using a retrospective 10% sample of prescriptions in Australian Pharmaceutical Benefits Scheme (PBS) data paliperidone palmitate 1-monthly (PP1M), paliperidone palmitate 3-monthly (PP3M), aripiprazole monohydrate (ARI), risperidone (RLAI) and olanzapine pamoate (OLAI).RESULTS:
Patients in the PP3M cohort were more persistent with treatment (p < 0.001). Median months of persistence PP3M (36 months); ARI (18 months); PP1M (11 months); OLAI (8 months); RLAI (4 months). Patients in the PP3M cohort were more adherent to treatment (p < 0.001) PP3M (78%); ARI (51%); PP1M (46%); OLAI (35%); RLAI (33%).CONCLUSIONS:
Patients on PP3M treatment showed comparatively longer persistence and better adherence. Treatments for schizophrenia with longer dosing intervals may provide patients with symptomatic stability that could allow for reduced hospitalisations/relapse and increased focus on functional recovery.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Esquizofrenia
/
Antipsicóticos
Limite:
Humans
País como assunto:
Oceania
Idioma:
En
Ano de publicação:
2023
Tipo de documento:
Article